Pricing Is Main Draw For Biosimilars In China Despite Regulatory Uncertainty
This article was originally published in PharmAsia News
Despite no word from China’s health regulators on a clear biosimilar approval pathway, competition is brewing. Chinese domestic biologics firms are stepping up to put biosimilars of blockbusters Herceptin and MabThera in front of regulators.
You may also be interested in...
As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.
China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.
With vaccines perhaps the ultimate weapon to fight the coronavirus, a developer in China sees a big chunk of investment with potentially more companies to see funding coming.